- Paper Report
- Open Access
Mechanisms of NF-?B activation in asthmatic bronchi
- Yassine Amrani1
© Biomed Central Ltd 2001
- Received: 24 November 2000
- Accepted: 19 September 2001
- Published: 19 September 2001
- Airway inflammation
The upregulated expression of cytokines, matrix modifying enzymes, and adhesion molecules observed in asthmatic airways is considered a key factor mediating the inflammation and remodeling processes that characterize the disease. The increased gene expression of these mediators may be modulated by potent transcription factors such as nuclear factor (NF)-?B. Using heaves-affected horses (an animal model of allergen-induced airway inflammation), the authors previously described that NF-?B activation is sustained in bronchial cells even after removal of the antigen and is strongly correlated with the severity of disease. In this study, the authors investigate the mechanisms of persistent NF-?B activation in this animal model.
The authors studied NF-?B activity by performing DNA binding assays in cells obtained from bronchial brushing samples (BBSs) and cultured for 3, 24 and 48 h. The authors demonstrated that activation of NF-?B (mainly as p65 homodimers) is sustained in cultured BBS cells of allergen-exposed animals. Regression analysis shows a strong correlation between the number of living granulocytes and NF-?B activity in BBS as well as in cultured cells. Pretreating cultured BBS cells with neutralizing antibodies against interleukin (IL)-1? and tumor necrosis factor (TNF)- a abrogates NF-?B activity and increases the cytoplasmic expression of I?B-?, a potent NF-?B inhibitor. In vitro translated I?B-? incubated with nuclear extracts of BBS cells from allergen-challenged animals completely abrogated NF-?B activity. The authors conclude that granulocytes are playing a central role in the persistence of NF-?B activation in all bronchial cells. This mainly occurs via the release of IL-1? and TNF-a that promote the degradation of the NF-?B inhibitor, I?B-?, thereby preventing NF-?B deactivation in all BBS-derived cells.
Bronchial brushings, immunostaining, EMSA, western blot